Radiation That Spares Healthy Brain Tissue for People With Brain Metastases
Studies quality of life and symptoms after sparing-style brain radiation in adults with brain metastases.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- NTS-WBRT in Brain Metastases
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 41 people, planned
- Started
- 8 Feb 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- NTS-WBRT (normal tissue sparing whole brain radiation therapy)
- Memantine
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid tumor that has spread to the brain, who need whole brain radiation. It studies quality of life and symptoms after a brain radiation that spares normal tissue, given with memantine.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Any number of brain metastases (cancer spread to the brain) from a solid tumor, needing whole brain radiation. Karnofsky Performance Status (a score of daily functioning) of 70 or more. Expected survival of more than 6 months.
- Earlier treatment
- Earlier focused radiation (SRS) or brain surgery may be allowed if the doctor agrees. Radiation starts at least 2 weeks after brain surgery. Earlier partial brain radiation is allowed if it covered less than 50% of the brain. People who had whole brain radiation before cannot join. Other cancer drugs before, during or after are allowed if the doctors agree.
- Biomarker or test result
- Women before menopause need a negative pregnancy test.
Main reasons for not taking part
- Cancer spread to the lining of the brain and spinal cord (leptomeningeal disease).
- Earlier whole brain radiation.
- Past or current use of memantine or other NMDA antagonists.
- Allergy to MRI contrast or unable to have an MRI.
- Pregnancy, or not willing to use birth control during radiation.
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy
- Age ≥ 18
- Karnofsky Performance Status ≥ 70
- Prior stereotactic radiosurgery (SRS) permissible per physician discretion
- Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy
- Prior partial brain radiation therapy permissible if target volume < 50% brain and per physician discretion
- Expectant > 6 months survival
- Ability to understand and the willingness to sign a written informed consent document
- Fluency in English, able to complete questionnaires and neurocognitive testing
- Ability to undergo MRI with gadolinium examination
- Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion
- Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians
- Negative pregnancy test for premenopausal women
Who cannot take part
- Prior whole brain radiation therapy
- Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy
- Concurrent participation in an investigational systemic therapy protocol
- Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)
- Known allergy to contrast used in imaging studies and/or inability to have MRI imaging
- Pre-existing or current use of memantine or other NMDA antagonists
This trial is currently available in United States.
- Massachusetts General Hospital Cancer CenterBoston, United StatesContact: Helen A Shih, MD,MS,MPHTaking people
About the trial
What the trial wants to find out
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).
Read full original descriptionShow less
This research study involves:
* NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
The group in the trial
- NTS-WBRT (normal tissue sparing whole brain radiation therapy) + MemantineTreatment being tested
Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive: * NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks. * Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor
Treatment: NTS-WBRT (normal tissue sparing whole brain radiation therapy) and Memantine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases
- Plain-language title
- Radiation That Spares Healthy Brain Tissue for People With Brain MetastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 16 April 2026